Treatment approaches to juvenile dermatomyositis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1509-1515

  Zipitis, C S ^a   Baildam, E M ^a   Ramanan, A V ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Calcinosis; Corticosteroids; Immunoglobulin; Juvenile dermatomyositis; Methotrexate

Indexed keywords

ALUMINUM HYDROXIDE; ASCORBIC ACID; AZATHIOPRINE; BIOLOGICAL FACTOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; EDETIC ACID; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; PROBENECID; STEROID; TACROLIMUS; VITAMIN D; WARFARIN;

ADRENAL INSUFFICIENCY; ALGORITHM; ANAPHYLAXIS; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; CALCINOSIS; CATARACT; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; CUSHING SYNDROME; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG FEVER; FRACTURE; GLAUCOMA; GROWTH RETARDATION; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INTRACRANIAL HYPERTENSION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MYOPATHY; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PEPTIC ULCER; PHOTOSENSITIVITY DISORDER; RETINA DISEASE; REVIEW; SKIN TOXICITY; VOMITING;

CONSENSUS; DERMATOMYOSITIS; EXPERT TESTIMONY; FORECASTING; HUMANS;

EID: 3543055334     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1509     Document Type: Review

References (100)

1. LAXER RM, FELDMAN BM: General and local scleroderma in children and dermatomyositis and associated syndromes. Curr. Opin. Rheumatol. (1997) 9:458-464.
2. KAIPIAINEN-SEPPANEN O, SAVOLAINEN A: Incidence of chronic juvenile rheumatic diseases in Finland during (1980-1990). Clin. Exp. Rheumatol. (1996) 14:441-444.
3. SYMMONS DPM, SILLS JA, DAVIS SM: The incidence of juvenile Dermatomyositis: results from a nation-wide study. Br. J. Rheumatol. (1995) 34:732-736.
4. CASSIDY JT, PETTY RE: Juvenile Dermatomyositis. In: Textbook of pediatric rheumatology (4th edn). Cassidy JT, Petty RE (Eds), Churchill Livingstone, Edinburgh, UK (2000):465-504.
5. PACHMAN LM, HAYFORD JR, CHUNG A et al.: Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J. Rheumatol. (1998) 25(6):1198-1204.
6. PELORO TM, MILLER OM, HAHN TF, NEWMAN ED: Juvenile dermatomyositis: A retrospective review of a 30-year experience. J. Am. Acad. Dermatol. (2001) 45:28-34.
7. HIKETA T, OHASHI M: Juvenile dermatomyositis-statistical observation of 105 patients with dermatomyositis. Nippon Hifuka Gakkai Zasshi (1991) 101(8):825-830.
8. SHEHATA R, AL-MAYOUF S, AL-DALAAN A, AL-MAZAID A, AL-BALAA S, BAHABRI S: Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin. Exp. Rheumatol. (1999) 17(1):115-118.
9. ANSELL BM: Juvenile Dermatomyositis. J. Rheumatol. (1992) 19(Suppl. 33):60-62.
10. BOHAN A, PETER JB: Polymyositis and dermatomyositis (1st part). N. Engl. J. Med. (1975) 292(7):344-347.
11. BOHAN A, PETER JB: Polymyositis and dermatomyositis (2nd part). N. Engl. J. Med. (1975) 292(8):403-407.
12. HANSON V: Dermatomyositis, scleroderma and polyarteritis nodosa. Clin. Rheum. Dis. (1976) 2:445-467.
13. SULLIVAN DB, CASSIDY JT, PETTY RE: Dermatomyositis in the pediatric patient. Arthritis Rheum. (1977) 20:327-331.
14. SPENCER CH, HANSON V, SINGSEN BH, BERNSTEIN BH, KORNREICH HK, KING KK: Course of treated juvenile dermatomyositis. J. Pediatr. (1984) 105:399-408.
15. TAIEB A, GUICHARD C, SALAMON R, MALEVILLE J: Prognosis of juvenile dermatomyositis. Pediatr. Dermatol. (1985) 2:275-281.
16. HUBER AM, LANG B, LEBLANC CM et al.: Medium and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. (2000) 43(3):541-549.
17. CAWKWELL GMD: Juvenile dermatomyositis and polymyositis: a survey of current practices in North America. J. Rheumatol. (2000) 27(Suppl. 58):84.
18. CAWKWELL GMD: Inflammatory myositis in children, including differential diagnosis. Curr. Opin. Rheumatol. (2000) 12:430-434.
19. COHEN BH, SEDWICK LA, BURDE RM: Retinopathy of dermatomyositis. J. Clin. Neuroopthalmol. (1985) 5:177-179.
20. TSE S, LUBERSKI S, GORDON M et al.: The arthritis of inflammatory childhood myositis syndromes. J. Rheumatol. (2001) 28:192-197.
21. SULLIVAN DB, CASSIDY JT, PETTY RE, BURT A: Prognosis in childhood dermatomyositis. J. Pediatr. (1972) 80:555-563.
22. PEREZ MD, ABRAMS SA, KOENING G, STUFF JE, O'BRIEN KO, ELLIS KJ: Mineral metabolism in children with dermatomyositis. J. Rheumatol. (1994) 21:2364-2369.
23. GOLDFIEN A: Adrenocorticosteroids and adrenocortical antagonists. In: Basic and Clinical Pharmacology (7th edn). Katzung BG (Ed.), Appleton and Lange, Stamford, Connecticut, USA (1998):635-652.
24. PACHMAN LM: Inflammatory myopathy in children. Rheum. Dis. Clin. North Am. (1994) 20:919-942.
25. RIDER LG, MILLER FW: Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. (1997) 23:619-655.
26. YANAGISAWA T, SUEISHI M, NAWATA Y et al.: Methylprednisolone pulse therapy in dermatomyositis. Dermatologica (1983) 167:47-51.
27. LAXER RM, STEIN LD, PETTY RE: Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum. (1987) 30:328-334.
28. HUANG JL: Long-term prognosis of patient with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. Clin. Exp. Rheumatol. (1999) 17:621-624.
29. LANG B, DOOLEY J: Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. J. Pediatr. (1996) 128:429-432.
30. PACHMAN LM, CALLEN AM, HAYFORD J et al.: Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy. Arthritis Rheum. (1994) 37(Suppl.):429.
31. ROMICKA AM: [Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children]. Pediatr. Pol. (1995) 70:243-248.
32. CLARKE AE, BLOCH DA, MEDSGER TA Jr, ODDIS CV: A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum. (1995) 38:1218-1224.
33. VILLALBA L, ADAMS EM: Update on therapy for refractory dermatomyositis and polymyositis. Curr. Opin. Rheumatol. (1996) 8:544-551.
34. WOO TY, CALLEN JP, VOORHEES JJ, BICKERS DR, HANNO R, HAWKINS C: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J. Am. Acad. Dermatol. (1984) 10:592-600.
35. OLSON NY, LINDSLEY CB: Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J. Rheumatol. (1989) 16:1545-1547.
36. MALAVIYA A, MANY A, SCHWARTZ R: Treatment of dermatomyositis with methotrexate. Lancet (1968) 2:485-488.
37. HILL R, WOOD W: Juvenile dermatomyositis. Can. Med. Assoc. J. (1970) 103:1152-1156.
38. ARNETT F, WHELTON J, ZIZIC T, STEVENS M: Methotrexate therapy in polymyositis. Ann. Rheum. Dis. (1973) 32:536-546.
39. METZGER A, BOHAN A, GOLDBERG L, BLUESTONE R, PEARSON C: Polymyositis and dermatomyositis: combined methotrexate and corricosteroid therapy. Ann. Intern. Med. (1981) 81:182-189.
40. JACOBS J: Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics (1977) 59:212-218.
41. NIAKAN E, PITNER S, WHITAKER J, BERTORINI T: Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology (1980) 30:286-291.
42. FISCHER T, RACHELEFSKY G, KLEIN R, PAULUS H, STIEHM E: Childhood dermatomyositis and polymyositis: treatment with methotrexate and prednisolone. Am. J. Dis. Child. (1979) 133:386-389.
43. MILLER LC, SISSON BA, TUCKER LB, DENARDO BA, SCHALLER JG: Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum. (1992) 35(10):1143-1149.
44. AL-MAYOUF S, AL-MAZIAD A, AL-DALAAN A et al.: Severe juvenile dermatomyositis: efficacy of early treatment with methotrexate. J. Rheumatol. (2000) 27(Suppl. 58):84.
45. CHABNER B, ALLEGRA C, CURT G et al.: Polyglutamation of methotrexate. J. Clin. Invest. (1985) 76:907-912.
46. ROSE C, SINGSEN B, EICHENFIELD A, GOLDSMITH D, ATHREYA B: Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J. Pediatr. (1990) 117:653-659.
47. GRAHAM L, MYONES B, RIVAS-CHACON R, PACHMAN L: Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J. Pediatr. (1992) 120:468-473.
48. GIANNINI E, BREWER E, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis. N. Engl. J. Med. (1992) 326:1043-1049.
49. FISLER RE, LIANG MG, FUHLBRIGGE RC, YALCINDAG A, SUNDEL RP: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J. Am. Acad. Dermatol. (2002) 47(4):505-511.
50. RAMANAN AV, CAMPBELL-WEBSTER N, TRAN D et al.: Initial managemnt of juvenile dermatomyositis using methotrexate and aggressively tapered prednisone. Pediatric Rheumatology Online Journal (2002) 1(4):124.
51. LANG BA, LAXER RM, MURPHY G, SILVERMAN ED, ROIFMAN CM: Treatment of dermatomyositis with intravenous gammaglobulin. Am. J. Med. (1991) 91:169-172.
52. COLLET E, DALAC S, MAERENS B, COURTOIS JM, IZAC M, LAMBERT D: Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br. J. Dermatol. (1994) 130:231-234.
53. ROIFMAN CM: Use of intravenous immune globulin in the therapy of children with rheumatological diseases. J. Clin. Immunol. (1995) 15:42S-51S.
54. SANSOME A, DUBOWITZ V: Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch. Dis. Child. (1995) 72:25-28.
55. TSAI MJ, LAI CC, LIN SC, CHIANG BL, CHOU CC, HSIEH KH: Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi (1997) 38:111-115.
56. AL-MAYOUF SM, LAXER RM, SCHNEIDER R, SILVERMAN ED, FELDMAN BM: Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. (2000) 27:2498-2503.
57. CHERIN P, HERSON S, WECHSLER B et al.: Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am. J. Med. (1991) 91:162-168.
58. CHERIN P, PIETTE JC, WECHSLER B et al.: Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J. Rheumatol. (1994) 21:1092-1097.
59. DALAKAS MC, ILLA I, DAMBROSIA JM et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. (1993) 329:1993-2000.
60. KATO E, SHINDO S, ETO Y et al.: Administration of immune globulin associated with aseptic meningitis. JAMA (1988) 259:3269-3271.
61. GOLDSMITH A, FELDMAN B, SINGH G et al.: Aseptic meningitis following intravenous immune globulin in children. Arthritis Rheum. (1991) 34:S121.
62. JACOBS JC: Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics (1977) 59:212-218.
63. BENSON MD, ALDO MA: Azathioprine therapy in polymyositis. Arch. Intern. Med. (1973):447-451.
64. CROWE WE, BOVE KE, LEVINSON JE, HILTON PK: Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthitis Rheum. (1982):126-139.
65. CRONIN ME, MILLER FW, HICKS JE, DALAKAS M, PLOTZ PH: The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J. Rheumatol. (1989) 16:1225-1228.
66. NAKASHIMA S, MORI M, MIYAMAE T et al.: Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis. Ryåumachi (2002) 42(6):895-902.
67. ZABEL P, LEIMENSTOLL G, GROSS WL: Cyclosporin for acute dermatomyositis. Lancet (1984) 1:343.
68. GIRARDIN E, DAYER JM, PAUNIER L: Cyclosporine for juvenile dermatomyositis. J. Pediatr. (1988) 112:165-166.
69. HECKMATT J, HASSON N, SAUNDERS C et al.: Cyclosporin in juvenile dermatomyositis. Lancet (1989) 1:1063-1066.
70. DANTZIG P: Juvenile dermatomyositis treated with cyclosporine. J. Am. Acad. Dermatol. (1990) 22:310-311.
71. ZELLER V, COHEN P, PRIEUR AM, GUILLEVIN L: Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and long-term follow-up of 6 cases. J. Rheumatol. (1996) 23:1424-1427.
72. REIFF A, RAWLINGS DJ, SHAHAM B et al.: Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile arthritis and juvenile dermatomyositis. J. Rheumatol. (1997) 24:2436-2443.
73. GRAU JM, HERRERO C, CASADEMONT J, FERNANDEZ-SOLA J, URBANO-MARQUEZ A: Cyclosporine A as first choice therapy for dermatomyositis. J. Rheumatol. (1994):381-382.
74. PETERS AM, HECKMATT JZ, HASSON N et al.: Renal haemodynamics of cyclosporin A nephrotoxicity in children with juvenile dermatomyositis. Clin. Sci. (Lond) (1991) 81:153-159.
75. OSTENSEN M, HOYERAAL HM, KASS E: Tolerance of cyclosporine A in children with refractory juvenile chronic arthritis. J. Rheumatol. (1988) 15:1536-1538.
76. PISTOIA V, BUONCOMPAGNI A, SCRIBANIS R et al.: Cyclosporine A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin. Exp. Rheumatol. (1992) 11:203-208.
77. MUKAMEL M, HOREV G, MIMOUNI M: New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J. Pediatr. (2001) 138:763-766.
78. HERD JK, VAUGHAN JH: Calcinosis universalis complicating dermatomyositis: its treatment with Na2EDTA. Report of two cases in children. Arthritis Rheum. (1964) 7:259.
79. NASSIM JR, CONNOLLY CK: Treatment of calcinosis universalis with aluminium hydroxide. Arch. Dis. Child. (1970) 45:118-121.
80. DENT CE, STAMP TC: Treatment of calcinosis circumscripta with probenecid. Br. Med. J. (1972) 1:216-218.
81. METZGER AL, SINGER FR, BLUESTONE R, PEARSON CM: Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma. N. Engl. J. Med. (1974) 291:1294-1296.
82. TABORN J, BOLE GG, THOMPSON GR: Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann. Intern. Med. (1978) 89:648-649.
83. MILLER G, HECKMATT JZ, DUBOWITZ V: Drug treatment of juvenile dermatomyositis. Arch. Dis. Child. (1983) 58:445-450.
84. MARTINEZ-CORDERO E, LOPEZ-ZEPEDA J, CHOZA-ROMERO F: Calcinosis in childhood dermatomyositis. Clin. Exp. Rheumatol. (1990):198-200.
85. NAKAGAWA T, TAKAIWA T: Calcinosis cutis in juvenile dermatomyositis responsive to aluminium hydroxide treatment. J. Dermatol. (1993) 20:558-560.
86. OLIVERI MB, PALERMO R, MAUTALEN C, HUBSCHER O: Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J. Rheumatol. (1996) 23(12):2152-2155.
87. EDDY MC, LEELAWATTANA R, MCALISTER WH, WHYTE MP: Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J. Clin. Endocrinol. Metab. (1997) 82(11):3536-3542.
88. HAREL L, HAREL G, KORENREIGH L, STRAUSSBERG R, AMIR J: Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J. Rheumatol. (2001) 28(5):1129-1132.
89. TAUSCHE A, MEURER M: Mycohenolate mofetil for dermatomyositis. Dermatol. (2001) 202:341-343.
90. HOLLAR C, JORIZZO J: Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J. Dermatol. Treat. (2004) 15(1):35-39.
91. YOSHIMASU T, OHTANI T, SAKAMOTO T, OSHIMA A, FURUKAWA F: Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J. Dermatol. (2002) 12(1):50-52.
92. UEDA M, MAKINODAN R, MATSUMURA M, ICHIHASHI M: Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br. J. Dermatol. (2003) 148(3):595-596.
93. TUTUNCU Z, MORGAN GJ Jr, KAVANAUGH A: Anti-TNF therapy for other inflammatory conditions. Clin. Exp. Rheumatol. (2002) 20(6):S146-S151.
94. MILLER M, MENDEZ E, KLEIN-GITELMAN MS, PACHMAN LM: Experience with etarnecept in chronic juvenile dermatomyositis: preliminary results. American College of Rheumatology 64th Annual Scientific Meeting, Philadelphia, USA, poster session, board number:293 (2000).
95. SHIMIZU T, TOMITA Y, SON K, NISHINARITA S, SAWADA S: Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin. Rheumatol. (2000) 19(5):352-359.
96. RAMANAN AV, FELDMAN BM: Clinical features and outcomes of juvenile dermatomyositis and other childhood myositis syndromes. Rheum. Dis. Clin. North Am. (2002) 28(4):833-857.
97. HOOGENDIJK JE, AMATO AA, LECKY BR et al.: 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. (2004) 14(5):337-345.
98. ISENBERG DA, ALLEN E, FAREWELL V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (2004) 43:49-54.
99. PEREZ MD, ABRAMS SA, KOENNING G, STUFF JE, O'BRIEN KO, ELLIS KJ: Mineral metabolism in children with dermatomyositis. J. Rheumatol. (1994) 21:2364-2369.
100. FISLER RE, LIANG MG, FUHLBRIGGE RC, YALCINDAG A, SUNDEL RP: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J. Am. Acad. Dermatol. (2002) 47(4):505-511.